Updated

Jazz Pharmaceuticals agreed to an $820 million transaction tied to an epilepsy treatment, expanding its neuroscience pipeline. The deal underscores continued consolidation and dealmaking activity among specialty pharmaceutical companies targeting neurological conditions. The move adds to Jazz's efforts to diversify its therapeutic portfolio beyond its existing product lines.